SEC Contract Filing

Filing Date: 2023-10-31

Document Content:
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>5
<FILENAME>d571974dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>STOCK AND WARRANT PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>THIS STOCK AND WARRANT PURCHASE AGREEMENT</B> (this &#147;<U>Agreement</U>&#148;) is dated as of October&nbsp;31, 2023, by and among
Aileron Therapeutics, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), and each purchaser identified on <U>Annex A</U> hereto (each, including its successors and assigns, a &#147;<U>Purchaser</U>&#148; and collectively, the
&#147;<U>Purchasers</U>&#148;). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>BACKGROUND </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A.&#8195;The Company and each Purchaser is executing and delivering this Agreement in reliance upon the exemption from securities registration
afforded by Section&nbsp;4(a)(2) of the Securities Act (as defined below), and Rule 506 of Regulation D (&#147;<U>Regulation D</U>&#148;) as promulgated by the United States Securities and Exchange Commission (the &#147;<U>Commission</U>&#148;)
under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B.&#8195;The Purchasers, severally and not jointly, wish to purchase, and the Company wishes to issue and sell,
upon the terms and conditions stated in this Agreement, (i)&nbsp;an aggregate of 4,707 shares (the &#147;<U>Shares</U>&#148;) of Series X <FONT STYLE="white-space:nowrap">Non-Voting</FONT> Convertible Preferred Stock, $0.001 par value per share (the
&#147;<U>Series X Preferred Stock</U>&#148;), of the Company, having the designation, preferences, conversion or other rights, voting powers, restrictions, limitations as to dividends, qualifications and terms and conditions as specified in the
Certificate of Designation, substantially in the form attached hereto as <U>Exhibit A</U> (the &#147;<U>Certificate of Designation</U>&#148;), which will be convertible into shares (the &#147;<U>Conversion Shares</U>&#148;) of the Company&#146;s
common stock, $0.001 par value per share (&#147;<U>Common Stock</U>&#148;), in accordance with the terms set forth in the Certificate of Designation, and (ii)&nbsp;warrants, in substantially the form attached hereto as <U>Exhibit B</U> (the
&#147;<U>Warrants</U>&#148;), to acquire up to 2,353,500 shares of Common Stock (the shares of Common Stock issuable upon exercise of, or otherwise pursuant to, the Warrants collectively are referred to herein as the &#147;<U>Warrant
Shares</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">C.&#8195;The Shares, the Conversion Shares, the Warrants and the Warrant Shares collectively are referred to herein as
the &#147;<U>Securities</U>.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">D.&#8195;Pursuant to the terms and conditions of the Certificate of Designation and the Warrants, as
applicable, the conversion of the Series X Preferred Stock and the issuance of the Warrant Shares shall be subject to receipt of the Requisite Stockholder Approval (as defined therein). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">E. The Company has engaged Clear Street LLC (&#147;<U>Clear Street</U>&#148;) and Brookline Capital Markets LLC (&#147;<U>Brookline</U>&#148;)
as its placement agents (the &#147;<U>Placement Agents</U>&#148;) for the offering of the Securities on a &#147;best efforts&#148; basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">F. &#8195;Prior to the Closing (as defined below): (i) the parties hereto shall execute and deliver a Registration Rights Agreement,
substantially in the form attached hereto as <U>Exhibit C</U> (the &#147;<U>Registration Rights Agreement</U>&#148;), pursuant to which, among other things, the Company will agree to provide certain registration rights with respect to the Conversion
Shares and Warrant Shares under the Securities Act and the rules and regulations promulgated thereunder and applicable state securities laws and (ii)&nbsp;the Company shall file with the Delaware Secretary of State the Certificate of Designation,
duly executed by an officer of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">G. &#8195;Immediately prior to the execution and delivery of this Agreement, the Company
entered into an Agreement and Plan of Merger by and among the Company, ALRN Merger Sub&nbsp;I, Inc., ALRN Merger Sub II, LLC, and Lung Therapeutics, Inc. (&#147;<U>Lung Tx</U>&#148;), in substantially the form attached hereto as <U>Exhibit E</U>
(the &#147;<U>Merger Agreement</U>&#148;), pursuant to which Lung Tx became a wholly-owned subsidiary of the Company by way of merger (the &#147;<U>Merger</U>&#148;). </P